VYNE Therapeutics’ (VYNE) “Buy” Rating Reiterated at HC Wainwright
HC Wainwright restated their buy rating on shares of VYNE Therapeutics (NASDAQ:VYNE – Free Report) in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $5.75 price objective on the stock. Separately, BTIG Research began coverage on shares of VYNE Therapeutics in a research report on Monday, November 18th. They set […]
HC Wainwright restated their buy rating on shares of VYNE Therapeutics (NASDAQ:VYNE – Free Report) in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $5.75 price objective on the stock. Separately, BTIG Research began coverage on shares of VYNE Therapeutics in a research report on Monday, November 18th. They set […]